Overview
- BioCryst reported ORLADEYO revenue of $158.2 million in the second quarter, a 10% year-over-year rise on a comparable basis, and kept its 2026 ORLADEYO guidance at $625 million to $645 million.
- The company began shipping ORLADEYO oral pellets for children and had received 47 pediatric prescriptions through July 31, with roughly half of patients completing prior authorizations.
- BioCryst completed enrollment in the pivotal ALPHA-ORBIT study of long-acting injectable navenibart for hereditary angioedema and expects top-line results in the third quarter of 2027.
- In June the company decided to end internal drug-discovery programs and will close its Birmingham research facility by the end of 2026, and it reduced 2026 non-GAAP operating-cost guidance to $420 million to $440 million.
- The quarter included a $55.7 million upfront licensing payment for navenibart in Europe, completion of the Astria integration, more than $350 million in cash and investments, and an enrolling BCX17725 study with early data expected by the end of 2026.